Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?

被引:25
作者
Piskorz, Daniel [1 ]
机构
[1] Rosario British Sanat Cardiol Inst, RA-2000 Rosario, Central Argenti, Argentina
关键词
Hypertensive mediated organ damage; Cardiovascular risk; Hypertension management; LEFT-VENTRICULAR MASS; CARDIOVASCULAR RISK; BLOOD-PRESSURE; SUBCLINICAL ATHEROSCLEROSIS; AORTIC STIFFNESS; VASCULAR EVENTS; HEART-FAILURE; REDUCTION; SPIRONOLACTONE; METAANALYSIS;
D O I
10.1007/s40292-020-00361-6
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The presence of hypertensive mediated organ damage is related to increased vascular risk and mortality and its prevention should be a therapeutic target and a surrogate marker of in/adequate blood pressure control. In old adult hypertensive patients the therapeutic target should be to prevent major cardiovascular events, but in young hypertensive subjects the focus should be pointed on preventing the development of hypertensive mediated organ damage, since most of the hard events are preceded by functional and structural tissues injury. Hypertension Guidelines of the European Society of Cardiology and European Society of Hypertension recognizes that some variables like electrocardiographic or echocardiographic left ventricle hypertrophy, chronic kidney disease or advance retinopathy, all considered as hypertensive mediated organ damage, may be modifiers of cardiovascular risk estimated by the SCORE system, and for that reason they should be screened in hypertensive patients. It is well known the problem of limited health systems financial resources in many low and even median income countries which precludes the possibilities of generalizing the search for hypertension mediated organ damage in all hypertensive patients. In these scenario the recommendation to perform a detailed screening should be critically evaluated. Some questions remained unanswered: the screening generalization of hypertensive mediated organ damage should modify the cardiovascular risk score of the patients, if its presence could modify the therapeutic approach, and as a consequence, if the treatment adjustment should prolong life expectancy and ameliorate the quality of life.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 45 条
  • [1] Ait-Oufella Hafid, 2010, J Hypertens, V28, P2336, DOI 10.1097/HJH.0b013e32833da2b2
  • [2] [Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
  • [3] Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
    Appel, Lawrence J.
    Wright, Jackson T., Jr.
    Greene, Tom
    Agodoa, Lawrence Y.
    Astor, Brad C.
    Bakris, George L.
    Cleveland, William H.
    Charleston, Jeanne
    Contreras, Gabriel
    Faulkner, Marquetta L.
    Gabbai, Francis B.
    Gassman, Jennifer J.
    Hebert, Lee A.
    Jamerson, Kenneth A.
    Kopple, Joel D.
    Kusek, John W.
    Lash, James P.
    Lea, Janice P.
    Lewis, Julia B.
    Lipkowitz, Michael S.
    Massry, Shaul G.
    Miller, Edgar R.
    Norris, Keith
    Phillips, Robert A.
    Pogue, Velvie A.
    Randall, Otelio S.
    Rostand, Stephen G.
    Smogorzewski, Miroslaw J.
    Toto, Robert D.
    Wang, Xuelei
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) : 918 - 929
  • [4] Benjamin IJ, 2019, LANCET, DOI [10.1016/S0140-6736(19),31629-0, DOI 10.1016/S0140-6736(19),31629-0]
  • [5] RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY
    BJORCK, S
    MULEC, H
    JOHNSEN, SA
    NORDEN, G
    AURELL, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823): : 339 - 343
  • [6] Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials
    Boekholdt, S. Matthijs
    Hovingh, G. Kees
    Mora, Samia
    Arsenault, Benoit J.
    Amarenco, Pierre
    Pedersen, Terje R.
    LaRosa, John C.
    Waters, David D.
    DeMicco, David A.
    Simes, R. John
    Keech, Antony C.
    Colquhoun, David
    Hitman, Graham A.
    Betteridge, John
    Clearfield, Michael B.
    Downs, John R.
    Colhoun, Helen M.
    Gotto, Antonio M., Jr.
    Ridker, Paul M.
    Grundy, Scott M.
    Kastelein, John J. P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (05) : 485 - 494
  • [7] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [8] Does Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials
    Costanzo, Pierluigi
    Perrone-Filardi, Pasquale
    Vassallo, Enrico
    Paolillo, Stefania
    Cesarano, Paolo
    Brevetti, Gregorio
    Chiariello, Massimo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (24) : 2006 - 2020
  • [9] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [10] Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation
    de Denus, Simon
    O'Meara, Eileen
    Desai, Akshay S.
    Claggett, Brian
    Lewis, Eldrin F.
    Leclair, Gregoire
    Jutras, Martin
    Lavoie, Joel
    Solomon, Scott D.
    Pitt, Bertram
    Pfeffer, Marc A.
    Rouleau, Jean L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17) : 1690 - 1692